Aquestive Therapeutics Inc (AQST)
4.57
+0.06
(+1.33%)
USD |
NASDAQ |
Nov 22, 10:28
Aquestive Therapeutics Enterprise Value: 364.60M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 364.60M |
| November 20, 2024 | 385.11M |
| November 19, 2024 | 392.86M |
| November 18, 2024 | 376.45M |
| November 15, 2024 | 358.22M |
| November 14, 2024 | 370.07M |
| November 13, 2024 | 393.78M |
| November 12, 2024 | 408.36M |
| November 11, 2024 | 415.66M |
| November 08, 2024 | 451.22M |
| November 07, 2024 | 416.57M |
| November 06, 2024 | 415.66M |
| November 05, 2024 | 386.94M |
| November 04, 2024 | 422.95M |
| November 01, 2024 | 456.69M |
| October 31, 2024 | 453.95M |
| October 30, 2024 | 467.63M |
| October 29, 2024 | 469.45M |
| October 28, 2024 | 453.95M |
| October 25, 2024 | 453.95M |
| October 24, 2024 | 453.04M |
| October 23, 2024 | 443.01M |
| October 22, 2024 | 418.39M |
| October 21, 2024 | 404.72M |
| October 18, 2024 | 412.01M |
| Date | Value |
|---|---|
| October 17, 2024 | 401.98M |
| October 16, 2024 | 402.89M |
| October 15, 2024 | 399.25M |
| October 14, 2024 | 394.69M |
| October 11, 2024 | 399.25M |
| October 10, 2024 | 381.92M |
| October 09, 2024 | 387.39M |
| October 08, 2024 | 401.53M |
| October 07, 2024 | 395.60M |
| October 04, 2024 | 404.72M |
| October 03, 2024 | 380.10M |
| October 02, 2024 | 390.13M |
| October 01, 2024 | 387.39M |
| September 30, 2024 | 407.45M |
| September 27, 2024 | 369.96M |
| September 26, 2024 | 395.46M |
| September 25, 2024 | 382.71M |
| September 24, 2024 | 399.10M |
| September 23, 2024 | 384.53M |
| September 20, 2024 | 403.65M |
| September 19, 2024 | 413.67M |
| September 18, 2024 | 390.91M |
| September 17, 2024 | 376.34M |
| September 16, 2024 | 391.82M |
| September 13, 2024 | 380.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
62.73M
Minimum
Mar 16 2020
469.45M
Maximum
Oct 29 2024
176.38M
Average
158.69M
Median
Feb 20 2020
Enterprise Value Benchmarks
| Rockwell Medical Inc | 61.68M |
| Cormedix Inc | 580.77M |
| Axogen Inc | 599.25M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.51M |
| Revenue (Quarterly) | 13.54M |
| Total Expenses (Quarterly) | 21.83M |
| EPS Diluted (Quarterly) | -0.13 |
| Gross Profit Margin (Quarterly) | 67.24% |
| Profit Margin (Quarterly) | -84.99% |
| Earnings Yield | -10.15% |
| Normalized Earnings Yield | -9.890 |